期刊文献+

阿哌沙班中8种已知杂质的HPLC法定量检测 被引量:5

Quantitative determination of eight known kinds of impurities in Apixaban by HPLC
下载PDF
导出
摘要 建立高效液相色谱法测定阿哌沙班中的8个已知杂质。色谱柱为Waters Xbridge Shield RP18(150mm×4.6mm,5μm);以乙腈-醋酸铵溶液为流动相,柱温:40℃,流量:1.0 m L/min,检测波长280 nm。阿哌沙班中8种杂质分离较好,与主峰均能有效分离,线性范围为0.01~11μg/m L;8种杂质的平均回收率分别为98.7%,105.3%,100.7%,111.4%,97.4%,103.4%,98.9%,97.6%,RSD分别为2.8%,4.3%,3.3%,4.5%,3.1%,4.0%,2.7%,3.1%。该法简便、准确、重复性好,可为阿哌沙班质量标准的制定提供参考。 To establish an HPLC method to determine eight kinds of impurities m Apixaban.Chromatographic column is Waters Xbridge Shield RP18 (150 mmx4.6 mm,5 μm), acetonitrile-ammonium acetate solution is mobile phase, The column temperature is 40 ℃ and the flow velocityis 1.0 mldmin, The detection wavelength is 280 nm. Eight kinds of impurities in Apixaban wereseparated from the primary front effectively and the linearity range was 0.01-11 μg/mL. The averagerecovery rates of the eight impurities are 98.7%, 105.3%, 100.7%111.4%, 97.4%, 103.4%,98.9%, 97.6%, and the RSDs were 2.8%, 4.3%, 3.3%, 4.5%, 3.1%, 4.0%, 2.7%, 3.1%. Thismethod is simple, accurate and of good repeatability. It provides quality standards for erythromyeinapixaban.
出处 《中国测试》 CAS 北大核心 2017年第3期36-42,共7页 China Measurement & Test
关键词 阿哌沙班 高效液相色谱法 杂质 回收率 分离 Apixaban high performance liquid chromatographic method impurities recovery rate separate
  • 相关文献

参考文献7

二级参考文献82

  • 1中国药典[S].2010年版.二部.附录ⅨJ.
  • 2Eikelboom JW,Weitz JI. New anticoagulants. Circulation,2010,121 : 1523-1532.
  • 3Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood,2010,115 : 15-20.
  • 4Granger CB, Armaganijan LV. Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. Cir- culation ,2012,125 : 159-164.
  • 5Hankey GJ, Eikelboom JW. New drugs and technologies:dabigatran etexilate : a new oral thrombin inhibitor. Circulation,2011,123 : 1436- 1450.
  • 6Wann LS,Curtis AB,Ellenbogen KA,et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation ( update on dabigatran) : a report of the American College of Cardiolo- gy Foundation/American Heart Association Task Force on Practice Guidelines. Circulation ,2011,123 : 1144-1150.
  • 7Perzborn E, Roehfig S, Straub A, et al. Rivaroxaban : a new oral factor X a inhibitor. Arteriosc|er Thromb Vasc Biol,2010,30:376-381.
  • 8Connolly SJ,Ezekowitz MD, Yusuf S, et al. The RE-LY Steering Com- mittee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med,2009,361 : 1139-1151.
  • 9Patel MR, Mahaffey KW, Garg J, et al. For the ROCKET AF Investiga- tors. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med,2011,365 :883-891.
  • 10Connolly SJ,Eikelboom J,Joyner C, et al. For the AVERROES Steer- ing Committee and Investigators. Apixaban in patients with atrial fibril- lation. N Engl J Med,2011,364:806-817.

共引文献54

同被引文献23

引证文献5

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部